Sanders, a vocal critic of high drug prices, had written to Florida-based Catalyst earlier this month, asking it to justify its price for Firdapse, a medication for a rare neuromuscular disease that affects about one in 100,000 people in the United States. It was also one of the campaign promises made by President Donald Trump in the 2016 elections. Last month, the Trump administration proposed a rule to overhaul the industry’s system of rebates, or discounts, while Sanders unveiled legislation aimed at lowering drug prices.
